Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 11/20 | 0.45 |
| ▸ | FPR1 | P21462 | 8/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22650382 | 0.87 | FPR2 (0.43) | FPR2FPR1F2F10PRSS1 | |
| SCHEMBL14022306 | 0.84 | FPR2 (0.45) | FPR2FPR1F2F10PRSS1 | |
| SCHEMBL23168389 | 0.81 | FPR2 (0.56) | FPR2FPR1F2F10PRSS1 | |
| SCHEMBL18963928 | 0.81 | FPR2 (0.48) | FPR2FPR1F2F10PRSS1 | |
| SCHEMBL18963926 | 0.81 | FPR2 (0.48) | FPR2FPR1F2F10PRSS1 | |
| SCHEMBL23168555 | 0.80 | FPR2 (0.43) | FPR2FPR1F10 | |
| SCHEMBL5021029 | 0.80 | FPR2 (0.49) | FPR2FPR1F2F10PRSS1 | |
| SCHEMBL6817997 | 0.80 | FPR2 (0.49) | FPR2FPR1F2F10PRSS1 | |
| SCHEMBL22179666 | 0.80 | FPR2 (0.42) | FPR2FPR1F10 | |
| SCHEMBL31019171 | 0.80 | FPR2 (0.41) | FPR2FPR1F2F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |